[1] International Lymphoma Study Group. A clinical evaluation of the international lymphoma study group classification of nonHodgkin′s lymphoma. The nonHodgkin′s lymphoma classification project[J]. Blood, 1997, 89(11): 3909-3918.
[2] Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. Blood, 2011, 117(19): 5019-5032.
[3] Dreyling M, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and followup[J]. Ann Oncol, 2009, 20 Suppl 4: 119-120.
[4] Heinzelmann F, Engelhard M, Ottinger H, et al. Nodal follicular lymphoma: the role of radiotherapy for stages Ⅰ and Ⅱ[J]. Strahlenther Onkol, 2010, 186(4): 191-196.
[5] Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage lowgrade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis[J]. Cancer, 2010, 116(16): 3843-3851.
[6] Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and followup[J]. Ann Oncol, 2014, 25 Suppl 3: 76-82.
[7] Dancey JE, Dodd LE, Ford R, et al. Recommendations for the assessment of progression in randomised cancer treatment trials[J]. Eur J Cancer, 2009, 45(2): 281-289.
[8] Saad ED, Katz A. Progressionfree survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined[J]. Ann Oncol, 2009, 20(3): 460-464.
[9] Eich HT, Heimann M, Stutzer H, et al. Longterm outcome and prognostic factors in earlystage nodal lowgrade nonhodgkin′s lymphomas treated with radiation therapy[J]. Strahlenther Onkol, 2009, 185(5): 288-295.
[10] Tsang RW, Gospodarowicz MK. Lowgrade nonhodgkin lymphomas[J]. Semin Radiat Oncol, 2007, 17(3): 198-205.
[11] Tsang RW, Gospodarowicz MK. Radiation therapy for localized lowgrade nonHodgkin′s lymphomas[J]. Hematol Oncol, 2005, 23(1): 10-17.
[12] Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the princess margaret hospital experience[J]. Int J Radiat Oncol Biol Phys, 1984, 10(4): 489-497.
[13] Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of firstline management strategies for stage Ⅰ follicular lymphoma: analysis of the national lymphoCare study[J]. J Clin Oncol, 2012, 30(27): 3368-3375.
[14] WitzensHarig M, Hensel M, Unterhalt M, et al. Treatment of limited stage follicular lymphoma with rituximab immunotherapy and involved field radiotherapy in a prospective multicenter phase Ⅱ trialMIR trial[J]. BMC Cancer, 2011, 11: 87.
[15] Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in nonHodgkin lymphoma: a randomised phase Ⅲ trial[J]. Radiother Oncol, 2011, 100(1): 86-92. |